Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose glucocorticoids for moderate to severe COVID-19 pneumonia
IRCT20080901001165N52Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone and prednisolone in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoint: Need to receive ICU service. Started Apr 2020; status: completed.
02
Drugs
methylprednisoloneprednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on IRCT20080901001165N52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080901001165N52.